https://www.selleckchem.com/pr....oducts/indoximod-nlg
3%). However, the primary safety endpoint was not achieved (p = 0.131), primarily attributable to the greater surgical complexity of the M-Trap patient population. 62% of recurrent patients demonstrated tumor cell capture in at least one device with a minimal tumor cell infiltration. No other long-term device-related adverse events were reported. The secondary performance endpoint demonstrated a lack of disease focalization. The M-Trap technology failed to meet its primary safety objective, although when adjusted for surgical
Like
Comment
Share
